Literature DB >> 10457196

The role of B7 costimulation in T-cell immunity.

N L Harris1, F Ronchese.   

Abstract

CD4+ T cells are considered to be the major controlling element of the adaptive immune response. They recognize foreign peptides by interaction of the T cell receptor (TCR) with peptide complexed to major histocompatibility complex (MHC) class II molecules on the surface of antigen presenting cells (APC). Once activated, CD4+ T cells orchestrate the various phases of the immune response. They are responsible for the production of numerous cytokines, which activate specific immune effector cell populations including B cells, eosinophils, mast cells and macrophages. Not surprisingly, the activation of CD4+ T cells needs to be tightly regulated and is subject to finely tuned control mechanisms. The requirement for a second or 'costimulatory' signal, in addition to the antigenic signal, provides a key element for the exquisite control of T cell activation. One of the major signalling pathways responsible for delivery of this costimulatory signal is induced by interaction of CD28 on T cells with B7 molecules found only on APC. The present review outlines our current understanding of the physiological role of B7 costimulatory signals in regulating CD4+ T cell responses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10457196     DOI: 10.1046/j.1440-1711.1999.00835.x

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  48 in total

Review 1.  Routes to transplant tolerance versus rejection; the role of cytokines.

Authors:  Patrick T Walsh; Terry B Strom; Laurence A Turka
Journal:  Immunity       Date:  2004-02       Impact factor: 31.745

2.  Characterisation of the T cell and dendritic cell repertoire in a murine model of mucopolysaccharidosis I (MPS I).

Authors:  Louise D Archer; Kia J Langford-Smith; William R Critchley; Brian W Bigger; James E Fildes
Journal:  J Inherit Metab Dis       Date:  2012-07-07       Impact factor: 4.982

3.  Temporal protein expression pattern in intracellular signalling cascade during T-cell activation: a computational study.

Authors:  Piyali Ganguli; Saikat Chowdhury; Rupa Bhowmick; Ram Rup Sarkar
Journal:  J Biosci       Date:  2015-10       Impact factor: 1.826

4.  HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells.

Authors:  Elena Martinelli; Claudia Cicala; Donald Van Ryk; Diana J Goode; Katilyn Macleod; James Arthos; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-20       Impact factor: 11.205

5.  Avidity of human T cell receptor engineered CD4(+) T cells drives T-helper differentiation fate.

Authors:  Patrick Adair; Yong Chan Kim; Kathleen P Pratt; David W Scott
Journal:  Cell Immunol       Date:  2015-10-23       Impact factor: 4.868

6.  Influence of costimulatory molecules on immune response to Leishmania major by human cells in vitro.

Authors:  C I Brodskyn; G K DeKrey; R G Titus
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 7.  Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.

Authors:  Damir Bojadzic; Peter Buchwald
Journal:  Curr Top Med Chem       Date:  2018       Impact factor: 3.295

8.  Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.

Authors:  Lucas A Horn; Tiha M Long; Ryan Atkinson; Virginia Clements; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Res       Date:  2017-11-09       Impact factor: 11.151

9.  The role of B7 family costimulatory molecules and indoleamine 2,3-dioxygenase in primary Sjögren's syndrome and systemic sclerosis.

Authors:  Nóra Legány; László Berta; László Kovács; Attila Balog; Gergely Toldi
Journal:  Immunol Res       Date:  2017-06       Impact factor: 2.829

10.  Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm.

Authors:  Muhammad Khattak; Rosalie Fisher; Samra Turajlic; James Larkin
Journal:  Ther Adv Med Oncol       Date:  2013-03       Impact factor: 8.168

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.